$VVOS

Vivos Therapeutics, Inc.

CIK:0001716166|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2026

Jun. 30, 2025

Jun. 30, 2026

Jun. 30, 2025

Revenue

Total revenue

$ 5,153

$ 3,820

$ 10,294

$ 6,835

Cost of sales (exclusive of depreciation and amortization shown separately below)

2,200

1,710

4,282

3,219

Gross profit

2,953

2,110

6,012

3,616

Operating expenses

General and administrative

7,113

6,409

16,083

11,298

Sales and marketing

155

260

404

615

Depreciation and amortization

510

306

965

483

Total operating expenses

7,778

6,975

17,452

12,396

Operating loss

(4,825)

(4,865)

(11,440)

(8,780)

Non-operating income (expense)

Other expense

(1,050)

(163)

(2,218)

(170)

Other income

352

384

Loss before income taxes

(5,523)

(5,013)

(13,274)

(8,877)

Net loss

(5,523)

(5,013)

(13,274)

(8,877)

Net loss attributable to non-controlling interest

(42)

(111)

Net loss attributable to stockholders

$ (5,481)

$ (5,013)

$ (13,163)

$ (8,877)

Net loss per share (basic)

$ (0.31)

$ (0.55)

$ (0.81)

$ (1.00)

Net loss per share (diluted)

$ (0.31)

$ (0.55)

$ (0.81)

$ (1.00)

Weighted average number of shares of Common Stock outstanding (basic)

17,681,945

9,087,202

16,166,450

8,842,604

Weighted average number of shares of Common Stock outstanding (diluted)

17,681,945

9,087,202

16,166,450

8,842,604

Product [Member]

Revenue

Total revenue

^[1]

$ 1,355

$ 1,885

$ 2,795

$ 3,698

Service [Member]

Revenue

Total revenue

$ 3,798

$ 1,935

$ 7,499

$ 3,137

[1]	Product revenue from the sale of appliances and preformed appliances is typically fixed at the inception of the contract and is recognized at the point in time when shipment of the related products occurs.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,274)	$ (8,877)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	201	559
Non-cash interest expense on promissory note		100
Depreciation and amortization	965	483
Fair value of common stock issued for services	586
Changes in operating assets and liabilities:
Accounts receivable	143	(269)
Operating lease liabilities, net	67	(67)
Prepaid expenses and other current assets	(227)	98
Deposits and other	(44)	64
Accounts payable	1,268	608
Accrued expenses	1,054	(127)
Other liabilities	(1)	646
Contract liability	104	(508)
Net cash used in operating activities	(9,158)	(7,290)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for acquisition, net of cash acquired of $0 and $865		(5,135)
Acquisitions of property and equipment	(434)	(893)
Net cash used in investing activities	(434)	(6,028)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of debt	3,025	9,642
Proceeds from issuance of common stock	633	347
Proceeds from issuance of preferred stock	1,105
Proceeds from issuance of warrants	1,562	1,699
Proceeds from issuance of pre-funded warrants	68	609
Proceeds from exercise of warrants	4,192
Payments for issuance costs		(837)
Reduction of debt liability	(1,220)
Payments for finance lease liability	(28)
Net cash provided by financing activities	9,337	11,460
Net (decrease) increase in cash and cash equivalents	(255)	(1,858)
Cash and cash equivalents at beginning of year	2,029	6,260
Cash and cash equivalents at end of period	1,774	4,402
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	568
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of promissory note	2,400	1,100
Conversion of debt to common stock	950
Common stock issued as consideration for acquisition		1,305
Contingent consideration as consideration for acquisition		$ 1,400

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 1,774	$ 2,029
Accounts receivable, net of allowance of $1,179 and $882, respectively	1,438	1,581
Prepaid expenses and other current assets	1,001	774
Total current assets	4,213	4,384
Long-term assets
Goodwill	8,572	8,572
Property and equipment, net	3,640	3,757
Operating lease right-of-use asset	3,809	4,166
Intangible assets, net	3,638	4,045
Deposits and other	272	228
Total assets	24,144	25,152
Current liabilities
Accounts payable	2,946	1,679
Accrued expenses	7,042	5,988
Contract liabilities	583	479
Current portion of operating lease liability	790	672
Current portion of financing lease liability	56	55
Current portion of debt	7,772	8,353
Other current liabilities	1,200	850
Total current liabilities	20,389	18,076
Long-term liabilities
Employee retention credit liability	2,904	2,904
Operating lease liability, net of current portion	3,438	3,840
Financing lease liability, net of current portion	83	113
Debt, net of current portion	366	469
Other liabilities	950	1,300
Total liabilities	28,130	26,702
Commitments and contingencies (Note 12)
Stockholders’ equity/(deficit)
Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; 3,608,495 shares issued and outstanding
Preferred Stock – additional paid in capital	1,105
Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 14,531,617 shares as of June 30, 2026 and 9,286,609 shares as December 31, 2025	1	1
Additional paid-in capital	133,599	123,866
Accumulated deficit	(138,520)	(125,357)
Total stockholders’ equity/(deficit)	(3,815)	(1,490)
Non-controlling interest	(171)	(60)
Total equity/(deficit)	(3,986)	(1,550)
Total liabilities and equity/(deficit)	$ 24,144	$ 25,152